ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DNL Diurnal Group Plc

27.30
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 27.30 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Diurnal Group PLC Notice of Results (4573J)

12/09/2016 7:01am

UK Regulatory


Diurnal (LSE:DNL)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Diurnal Charts.

TIDMDNL

RNS Number : 4573J

Diurnal Group PLC

12 September 2016

12 September 2016

Diurnal Group plc

("Diurnal" or the "Company")

Notice of Final Results

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2016 on Wednesday, 12 October 2016.

Please further information, please visit www.diurnal.co.uk or contact:

 
 Diurnal Group plc             +44 (0)20 3727 1000 
 Martin Whitaker, CEO 
 Ian Ardill, CFO 
 
 Numis Securities Ltd          +44 (0)20 7260 1000 
 Nominated Adviser: Michael 
  Meade, Freddie Barnfield, 
  Paul Gillam 
 Corporate Broking: James 
  Black 
 
 FTI Consulting                + 44 (0)20 3727 1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFFLAVIAIIR

(END) Dow Jones Newswires

September 12, 2016 02:01 ET (06:01 GMT)

1 Year Diurnal Chart

1 Year Diurnal Chart

1 Month Diurnal Chart

1 Month Diurnal Chart

Your Recent History

Delayed Upgrade Clock